Abstract
DNA microarrays are currently playing a central role in biomarker discovery and in the development of diagnostics for personalized medicine. Our vision is a technology that enables proteomics in the same revolutionary way that DNA microarrays enabled nucleic acid-based omics, allowing simple, reliable, sensitive, accurate, quantitative, and highly multiplexed measurements for the discovery of protein biomarkers and the development of new diagnostics to transform personalized medicine. We recently reached an important milestone, making unbiased protein biomarker discovery routine and fast. Microarrays played a prominent role in our experiments and will be central to the ongoing evolution of our platform. Our technology is powered by a new class of single-stranded DNA-based protein affinity binding reagents we call SOMAmers—slow off-rate modified aptamers. SOMAmers have a dual nature that is essential in our work: under normal conditions (e.g., physiologic in serum), SOMAmers fold into specific shapes that bind target proteins with high affinity (sub-nM K d), but when SOMAmers are denatured, they can be detected and quantified by hybridizing to a standard DNA microarray.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Addona TA, Abbatiello SE, Schilling B et al (2009) Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 27:633–641. doi:10.1038/nbt.1546
Aebersold R (2009) A stress test for mass spectrometry–based proteomics. Nat Methods 6:411–412. doi:10.1038/nmeth0609-411
Anderson NL (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1:845–867. doi:10.1074/mcp.R200007-MCP200
Anderson NL (2010) The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 56:177–185. doi:10.1373/clinchem.2009.126706
Bell AW, Deutsch EW, Au CE et al (2009) A HUPO test sample study reveals common problems in mass spectrometry-based proteomics. Nat Methods 6:423–430. doi:10.1038/nmeth.1333
Bock C, Coleman M, Collins B et al (2004) Photoaptamer arrays applied to multiplexed proteomic analysis. Proteomics 4:609–618. doi:10.1002/pmic.200300631
Boyle P, Levin B (2008) World cancer report. International Agency for Research on Cancer, Lyon
Brody EN, Gold L, Lawn RM et al (2010) High-content affinity-based proteomics: unlocking protein biomarker discovery. Expert Rev Mol Diagn 10:1013–1022. doi:10.1586/erm.10.89
Chaudhary K, Phadke G, Nistala R et al (2010) The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease. Curr Diab Rep 10:37–42. doi:10.1007/s11892-009-0080-z
Eaton BE, Gold L, Zichi DA (1995) Let’s get specific: the relationship between specificity and affinity. Chem Biol 2:633–638. doi:10.1016/S0031-9406(05)67026-5
Ellington AD, Szostak JW (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346:818–822. doi:10.1038/346818a0
Giannelli SV, Patel KV, Windham BG et al (2007) Magnitude of underascertainment of impaired kidney function in older adults with normal serum creatinine. J Am Geriatr Soc 55:816–823. doi:10.1111/j.1532-5415.2007.01196.x
Glass DJ (2010) A critique of the hypothesis, and a defense of the question, as a framework for experimentation. Clin Chem 56:1080–1085. doi:10.1373/clinchem.2010.144477
Gold L, Ayers D, Bertino J et al (2010a) Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 5:e15004. doi:10.1371/journal.pone.0015004
Gold L, Janjic N, Jarvis T et al (2010b) Aptamers and the RNA world, past and present. In: Atkins JF, Gesteland RF, Cech T (eds) RNA worlds, 3rd edn. Cold Spring Harbor, NY, pp 343–341
Golden MC, Collins BD, Willis MC, Koch TH (2000) Diagnostic potential of PhotoSELEX-evolved ssDNA aptamers. J Biotechnol 81:167–178
Hopfield JJ (1974) Kinetic proofreading: a new mechanism for reducing errors in biosynthetic processes requiring high specificity. Proc Natl Acad Sci USA 71:4135–4139
Hopfield JJ, Yamane T, Yue V, Coutts SM (1976) Direct experimental evidence for kinetic proofreading in amino acylation of tRNAIle. Proc Natl Acad Sci USA 73:1164–1168
Huang D-B, Vu D, Cassiday LA et al (2003) Crystal structure of NF-kappaB (p50)2 complexed to a high-affinity RNA aptamer. Proc Natl Acad Sci USA 100:9268–9273. doi:10.1073/pnas.1632011100
Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96. doi:10.3322/CA.2007.0010
Kassis ES, Vaporciyan AA, Swisher SG et al (2009) Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population. J Thorac Cardiovasc Surg 138:412–418. doi:10.1016/j.jtcvs.2009.01.033, e1-2
Keeney TR, Bock C, Gold L et al (2009) Automation of the SomaLogic proteomics assay: a platform for biomarker discovery. J Assoc Lab Automation 14:360–366. doi:10.1016/j.jala.2009.05.003
Kell DB, Oliver SG (2004) Here is the evidence, now what is the hypothesis? the complementary roles of inductive and hypothesis-driven science in the post-genomic era. Bioessays 26:99–105. doi:10.1002/bies.10385
Kraemer S, Vaught JD, Bock C et al (2011) From SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmer-based, streamlined multiplex proteomic assay. PLoS One 6:e26332. doi:10.1371/journal.pone.0026332
Lander AD (2010) The edges of understanding. BMC Biology 8:40. doi:10.1186/1741-7007-8-40
Levey AS, Atkins R, Coresh J et al (2007) Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from kidney disease improving global outcomes. Kidney Int 72:247–259. doi:10.1038/sj.ki.5002343
Lin H, Lee E, Hestir K et al (2008) Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science(80-) 320:807–11. doi:10.1126/science.1154370
Liotta LA, Petricoin EF (2010) Mass spectrometry-based protein biomarker discovery and measurement: sensitivity is the greatest hurdle. Clinical Proteomics 6:4–5. doi:10.1007/s12014-010-9045-0
Long SB, Long MB, White RR, Sullenger BA (2008) Crystal structure of an RNA aptamer bound to thrombin. RNA 14:2504–2512. doi:10.1261/rna.1239308
Mitchell P (2010) Proteomics retrenches. Nat Biotechnol 28:665–670. doi:10.1038/nbt0710-665
Nabel GJ (2009) The Coordinates of truth. Science 326:53–54
Nickolas TL, Barasch J, Devarajan P (2008) Biomarkers in acute and chronic kidney disease. Curr Opin Nephrol Hypertens 17:127–132. doi:10.1097/MNH.0b013e3282f4e525
O’Farrell PH (1975) High resolution two-dimensional electrophoresis of proteins. J Biol Chem 250:4007–4021
Okada M, Nishio W, Sakamoto T et al (2005) Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection. J Thorac Cardiovasc Surg 129:87–93. doi:10.1016/j.jtcvs.2004.04.030
Ostroff R, Foreman T, Keeney TR et al (2010a) The stability of the circulating human proteome to variations in sample collection and handling procedures measured with an aptamer-based proteomics array. J Proteomics 73:649–666. doi:10.1016/j.jprot.2009.09.004
Ostroff RM, Bigbee WL, Franklin W et al (2010b) Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One 5:e15003. doi:10.1371/journal.pone.0015003
Pan S, Aebersold R, Chen R et al (2009) Mass spectrometry based targeted protein quantification: methods and applications. J Proteome Res 8:787–797. doi:10.1021/pr800538n
Pascual M, Steiger G, Estreicher J et al (1988) Metabolism of complement factor D in renal failure. Kidney Int 34:529–536
Pepe MS, Feng Z (2011) Improving biomarker identification with better designs and reporting. Clin Chem 1095:1093–1095. doi:10.1373/clinchem.2011.164657
Pepe MS, Etzioni R, Feng Z et al (2001) Phases of biomarker development for early detection of cancer OF. Cancer 93:1054–1061
Pepe MS, Feng Z, Janes H et al (2008) Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 100:1432–1438. doi:10.1093/jnci/djn326
Petach H (2002) Dimensionality is the issue: use of photoaptamers in protein microarrays. Curr Opin Biotechnol 13:309–314. doi:10.1016/S0958-1669(02)00329-4
Ransohoff DF (2004) Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 4:309–314. doi:10.1038/nrc1322
Ransohoff DF, Gourlay ML (2010) Sources of bias in specimens for research about molecular markers for cancer. J Clin Oncol 28:698–704. doi:10.1200/JCO.2009.25.6065
Rifai N, Gillette MA, Carr SA (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 24:971–983. doi:10.1038/nbt1235
Service RF (2008) Proteomics ponders prime time. Science (80-) 321:1758–1761
Silberring J, Ciborowski P (2010) Biomarker discovery and clinical proteomics. Trends Anal Chem 29:128. doi:10.1016/j.trac.2009.11.007
Smith D (2002) Sensitivity and specificity of photoaptamer probes. Mol Cell Proteomics 2:11–18. doi:10.1074/mcp.M200059-MCP200
Smith D, Collins BD, Heil J, Koch TH (2003) Sensitivity and specificity of photoaptamer probes. Mol Cell Proteomics 2:11–18
Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505–510
van Riemsdijk-van Overbeeke IC, Baan CC, Hesse CJ et al (2000) TNF-alpha: mRNA, plasma protein levels and soluble receptors in patients on chronic hemodialysis, on CAPD and with end-stage renal failure. Clin Nephrol 53:115–123
Vaught JD, Dewey T, Eaton BE (2004) T7 RNA polymerase transcription with 5-position modified UTP derivatives. J Am Chem Soc 126:11231–11237. doi:10.1021/ja049009h
Vaught JD, Bock C, Carter J et al (2010) Expanding the chemistry of DNA for in vitro selection. J Am Chem Soc 132:4141–4151. doi:10.1021/ja908035g
Venturoli D, Rippe B (2005) Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability. Am J Physiol Renal Physiol 288:F605–F613. doi:10.1152/ajprenal.00171.2004
Vicens Q, Cech TR (2006) Atomic level architecture of group I introns revealed. Trends Biochem Sci 31:41–51. doi:10.1016/j.tibs.2005.11.008
Zichi D, Koga T, Greef C et al (2002) Photoaptamer technology: development of multiplexed microarray protein assays. Clin Chem 48:1865–1867
Zichi D, Eaton B, Singer B, Gold L (2008) Proteomics and diagnostics: let’s get specific, again. Curr Opin Chem Biol 12:78–85. doi:10.1016/j.cbpa.2008.01.016
Acknowledgments
We thank all our colleagues who have contributed to developing SomaLogic’s unbiased, high-scale proteomics technology and in particular those who developed SOMAmers and the SOMAscan proteomics assay for biomarker discovery. We especially thank Nebojsa Janjic, Nick Saccomano, and Steve Williams and their research groups for their dedicated efforts in developing this technology.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Walker, J.J., Brody, E.N., Gold, L. (2012). Slow Off-Rate Modified Aptamer Arrays for Biomarker Discovery and Diagnostic Applications. In: Jordan, B. (eds) Microarrays in Diagnostics and Biomarker Development. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-28203-4_8
Download citation
DOI: https://doi.org/10.1007/978-3-642-28203-4_8
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-28202-7
Online ISBN: 978-3-642-28203-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)